广东肇庆星湖生物科技股份有限公司关于2025年度预计担保事项的进展公告

Core Viewpoint - The company has approved a guarantee plan for the year 2025, which includes significant amounts allocated to subsidiaries for business development needs [1][11]. Group 1: Guarantee Amounts and Adjustments - The company plans to provide a guarantee of 710 million yuan to Heilongjiang Yipin Trading Co., Ltd. and 1.1 billion yuan to Inner Mongolia Yipin Biotechnology Co., Ltd. for the year 2025 [1]. - A total of 160 million yuan in guarantee capacity from Ningxia Yipin Trading Co., Ltd. will be reallocated to Heilongjiang Yipin Trading Co., Ltd. due to its asset-liability ratio exceeding 70% [1]. Group 2: Actual Guarantee Situation - In the fourth quarter of 2025, the company signed new guarantee contracts amounting to 330 million yuan, with an actual usage of 220 million yuan [1]. Group 3: Guarantee Recipients and Their Status - Heilongjiang Yipin Trading Co., Ltd. and Inner Mongolia Yipin Biotechnology Co., Ltd. are the main recipients of the guarantees, both of which are controlled subsidiaries of the company [3][11]. - As of the announcement date, the guarantee recipients are not listed as dishonest executors [4]. Group 4: Guarantee Agreement Details - The company has entered into guarantee agreements with various banks, including a 50 million yuan guarantee with Agricultural Bank of China and an 80 million yuan guarantee with Huaxia Bank [4][7]. - The guarantees cover a range of obligations including principal, interest, penalties, and other costs associated with debt recovery [6][10]. Group 5: Necessity and Reasonableness of Guarantees - The planned guarantees are deemed necessary for meeting the operational funding needs of the company and its subsidiaries, aligning with the company's overall business development strategy [11]. - The board of directors believes that the guarantees will not adversely affect the company's normal operations or financial condition [11]. Group 6: Cumulative Guarantee Situation - As of December 31, 2025, the total external guarantee balance is 2.940767 billion yuan, accounting for 37.34% of the company's latest audited net assets attributable to shareholders [11]. - There are no overdue guarantees or litigation related to guarantees outside the consolidated financial statements [11].

广东肇庆星湖生物科技股份有限公司关于2025年度预计担保事项的进展公告 - Reportify